OssDsign publishes Q2 2026 interim report
The company reports a net revenue of 37.8 MSEK and an adjusted operating result of -12 MSEK for the second quarter of 2026.
See the latest news and media coverage for OssDsign. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer and provider of orthobiologics products
ossdsign.comLast updated
In short: OssDsign posted flat Q2 2026 sales as shares fell 6%, while its PROPEL registry topped 400 patients.
The company reports a net revenue of 37.8 MSEK and an adjusted operating result of -12 MSEK for the second quarter of 2026.
The company reports a revenue decline of 3.6% and an adjusted operating loss. CEO Mark Waugh comments on the challenges and planned measures.
Revenue declined 3.6% due to sales team issues and account slowdowns, with EBIT below market expectations until the full report in May.
Revenue increased by 45% to SEK 180 million. Mark Waugh appointed as new CEO, and expansion in the US continues.
OssDsign said second-quarter sales were flat from the first quarter and in line with management guidance, but the orthopedic bone graft maker continued to face...
The medical technology company Ossdsign, which operates within implants for cranial reconstruction, reports an adjusted operating result of minus 12.0 million...
OssDsign AB (publ) announces that the interim report for Q1 2026 is now available as a PDF on the company's website A PDF version is...
OssDsign AB (publ.) announces today that the preliminary revenue for the period January-March 2026 amounts to 4.035 million USD or 36.880 million SEK.
Track OssDsign and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to OssDsign and other trending companies.